Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Vermont residents can access Ozempic (semaglutide 1mg) entirely online through our physician-supervised telehealth program. Ozempic is FDA-approved and clinically proven to reduce body weight by an average of 14.9% over 68 weeks. Our board-certified physicians prescribe the exact semaglutide dosing schedule — starting at 0.25mg and escalating to the 1mg maintenance dose — appropriate for your health profile.
Getting your Ozempic 1mg prescription in Vermont is simple: complete our online health intake, receive physician review within 24–48 hours, and receive your medication delivered to any VT address within 2–5 business days.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Semaglutide — 1mg Maintenance Dose
Ozempic 1mg is FDA-approved once-weekly semaglutide for weight management in Vermont adults with obesity. With guided dose escalation from 0.25mg, patients achieve an average of 14.9% body weight reduction over 68 weeks (STEP 1 trial). Physician-prescribed and pharmacy-delivered statewide.
Get Ozempic 1mg in VTHigher-Dose Semaglutide — FDA-Approved for Obesity
Wegovy 2.4mg is semaglutide at a higher maintenance dose, specifically FDA-approved for chronic weight management in Vermont. Clinical trials show an average 15–17% body weight reduction. Your VT physician will recommend whether Ozempic 1mg or Wegovy 2.4mg is best for your profile.
Explore Wegovy in VTDual GLP-1/GIP Agonist — Up to 22% Weight Loss
For Vermont patients seeking maximum weight loss efficacy, tirzepatide (Mounjaro®/Zepbound®) is also available. This dual GLP-1/GIP receptor agonist achieves up to 22.5% body weight reduction in clinical trials — the highest result of any FDA-approved weight loss medication.
Explore Tirzepatide in VTGLP-1 receptor agonists are among the most rigorously studied obesity treatments, with evidence from placebo-controlled trials published in the New England Journal of Medicine:
authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in .
Yes. Vermont residents can access Ozempic 1mg (semaglutide) entirely online through our physician-supervised telehealth program. Our board-certified physicians prescribe FDA-approved Ozempic and deliver it to any VT address within 2–5 business days — no in-person visit required.
Most Vermont patients reach the Ozempic 1mg maintenance dose within 8–12 weeks of starting treatment. The typical escalation schedule begins at 0.25mg for 4 weeks, increases to 0.5mg for 4+ weeks, then advances to 1mg. Your VT physician adjusts the timeline based on your individual tolerance and response.
Clinical data from the STEP 1 trial shows an average 14.9% body weight reduction over 68 weeks with semaglutide 1mg. Over 80% of participants lost at least 5% of their body weight. Individual results for Vermont patients vary based on adherence, diet, exercise, and individual metabolic response.
Insurance coverage for Ozempic in Vermont varies by plan and indication. Ozempic is more commonly covered for type 2 diabetes management than for weight loss alone. Our VT telehealth physicians can provide documentation to support insurance pre-authorization requests and can also help you explore cash-pay pricing options.
Local weight loss and GLP-1 providers serving the Vermont area, based on Google Business listings.
South Burlington, VT
(802) 234-1277
5/5 ★ (5 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
